Literature DB >> 3601370

Long-term follow-up of pseudoexfoliation and the development of elevated intraocular pressure.

J C Henry, T Krupin, M Schmitt, J Lauffer, E Miller, M Q Ewing, H G Scheie.   

Abstract

A retrospective study was performed to determine the long-term course of pseudoexfoliation (PEX) as it relates to both the development of elevated intraocular pressure and to the initial appearance of exfoliation material in normal fellow eyes of patients with PEX. Six hundred eighty patients seen from 1940 through 1980 were diagnosed as having PEX. Patients were excluded from long-term study if there was a diagnosis of glaucoma prior to examination at our institution (199 patients), if glaucoma was present at the time of diagnosis of PEX (40 patients), if there was a history of prior intraocular surgery or disease (19 patients), or if there was only one ocular examination performed (75 patients). The remaining 347 patients with initially normal intraocular pressures were followed over time and consisted of 225 patients with unilateral PEX and 122 patients with bilateral PEX (a total of 469 PEX eyes). Life table (actuarial) analysis was used for data evaluation. During the course of the study, 32 (14%) of the unilateral cases of PEX became bilateral. The cumulative probability of a normal fellow eye developing PEX increased over time, with a 6.8% cumulative probability in 5 years and a 16.8% cumulative probability in 10 years. Elevated intraocular pressure developed in 35 patients (44 eyes) during the study. The cumulative probability for eyes with PEX to develop elevated intraocular pressure was 5.3% in 5 years and increased to 15.4% in 10 years. These probabilities predict that patients with PEX have a higher incidence of developing elevated intraocular pressure than would be expected in patients without PEX of similar age.

Entities:  

Mesh:

Year:  1987        PMID: 3601370     DOI: 10.1016/s0161-6420(87)33413-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  21 in total

1.  Combined exfoliation and pigment dispersion: an overlap syndrome.

Authors:  R Mudumbai; J M Liebmann; R Ritch
Journal:  Trans Am Ophthalmol Soc       Date:  1999

Review 2.  The medical and surgical management of pseudoexfoliation glaucoma.

Authors:  Manishi A Desai; Richard K Lee
Journal:  Int Ophthalmol Clin       Date:  2008

3.  Managing advanced unilateral pseudoexfoliative glaucoma.

Authors:  André Marques
Journal:  BMJ Case Rep       Date:  2014-05-21

4.  Choroidal thickness changes in patients with pseudoexfoliation syndrome.

Authors:  Mehmet Ozgur Zengin; Esat Cinar; Eyyup Karahan; Ibrahim Tuncer; Sami Yilmaz; Tolga Kocaturk; Cem Kucukerdonmez
Journal:  Int Ophthalmol       Date:  2014-07-25       Impact factor: 2.031

Review 5.  Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.

Authors:  J A Balfour; M I Wilde
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

6.  Peripapillary atrophy in unilateral capsular glaucoma.

Authors:  P Puska; C Raitta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-11       Impact factor: 3.117

7.  Trabecular aspiration: a new surgical approach to improve trabecular facility in pseudoexfoliation glaucoma.

Authors:  P C Jacobi; G K Krieglstein
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

8.  Exfoliation syndrome and occludable angles.

Authors:  R Ritch
Journal:  Trans Am Ophthalmol Soc       Date:  1994

9.  Aqueous humour levels of ghrelin in exfoliation syndrome and exfoliation glaucoma patients.

Authors:  Ayşe Vural Ozeç; Ayhan Dursun; Mustafa Ilker Toker; Yüksel Demirci; Aysen Topalkara; Haydar Erdoğan; Mustafa Kemal Arıcı; Taner Ersalcan
Journal:  Jpn J Ophthalmol       Date:  2014-05-08       Impact factor: 2.447

10.  The cornea in exfoliation syndrome.

Authors:  M Stefaniotou; C Kalogeropoulos; N Razis; K Psilas
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.